Year: 2025

Brilliant Earth Reports Fourth Quarter and Fiscal Year 2024 Results

Written by Customer Service on March 12, 2025. Posted in Earnings Releases And Operating Results.

Delivered Net Sales at High End of Guidance RangeDrove 10% Year-Over-Year Total Order Growth in Q4 2024Exceeded Profitability Expectations and Increased Q4 2024 Gross Margin by 90 bps Year-Over-Year to 59.6%Generated Q4 2024 GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $0.04Provides Q1 and Full Year 2025 Guidance SAN FRANCISCO, March 12, 2025 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced financial results for the three and twelve months ended December 31, 2024. Fourth Quarter and Fiscal Year 2024 Highlights (quarterly and annual periods ended December 31, 2024):Delivered Net Sales of $119.5 million and $422.2 million in the fourth quarter and fiscal year, respectivelyTotal orders grew...

Berry Corporation Reports Fourth Quarter and Full Year 2024 Financial and Operational Results, Year-End Reserves and 2025 Outlook

Written by Customer Service on March 12, 2025. Posted in Earnings Releases And Operating Results.

DALLAS, March 12, 2025 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) today announced financial and operating results for the fourth quarter and full year 2024, as well as a quarterly cash dividend of $0.03 per share. Berry has provided a supplemental slide deck on its results, which can be found at www.bry.com. The Company plans to host a conference call and webcast to discuss its fourth quarter and full year 2024 results, as well as its 2025 outlook, at 10:00 a.m. CT, Thursday, March 13, 2025. Details can be found in this release. Full Year 2024 HighlightsDelivered results better than the midpoint of guidance on production, operational expenses, G&A and capital expenditures Reported net income of $19 million, or $0.25 per diluted share and Adjusted Net Income(1) of $52 million, or $0.68...

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Written by Customer Service on March 12, 2025. Posted in Earnings Releases And Operating Results.

– Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile – – Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) – – Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium – – FDA approval of Investigational Device Exemption (IDE) and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed locally advanced or...

Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

Written by Customer Service on March 12, 2025. Posted in Earnings Releases And Operating Results.

SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos EventsReported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025. Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives.Cash Guidance Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated...

Kalaris and AlloVir Announce Stockholder Approval of Merger

Written by Customer Service on March 12, 2025. Posted in Mergers And Acquisitions.

Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger,...

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

Written by Customer Service on March 12, 2025. Posted in Earnings Releases And Operating Results.

Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com. About...

CAISSE FRANCAISE DE FINANCEMENT LOCAL EMTN 2025-6

Written by Customer Service on March 12, 2025. Posted in Public Companies.

Paris, 12 March 2025 Capitalised terms used herein shall have the meaning specified for such terms in the Caisse Française de Financement Local base prospectus to the €75,000,000,000 Euro Medium Term Note Programme dated 8 July 2024 (the “Base Prospectus”). Caisse Française de Financement Local has decided to issue on 14 March 2025 – Euro 54,000,000 Callable Fixed Rate Obligations Foncières due 14 March 2050. The Base Prospectus dated 8 July 2024 and the supplements to the Base Prospectus dated 13 September 2024, 30 September 2024, 26 December 2024 and 27 February 2025 approved by the Autorité des Marchés Financiers are available on the website of the Issuer (https://www.caissefrancaisedefinancementlocal.fr/), at the registered office of the Issuer: 112-114, avenue Emile Zola, 75015 Paris, France, and at the office of the Paying Agent...

AMG Critical Materials N.V. Successfully Repurchases 40% Stake in its Subsidiary Graphit Kropfmühl

Written by Customer Service on March 12, 2025. Posted in Public Companies.

Amsterdam, 12 March 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to confirm the transaction initially announced on December 23, 2024 to repurchase a 40% ownership interest in Graphit Kropfmühl GmbH, owned by an affiliate of Alterna Capital Partners, has been successfully completed as of March 12, 2025 in accordance with the announced terms. About AMG AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO2 in aerospace engines, as well as critical materials addressing CO2 reduction in a variety of other end use markets. AMG’s...

AMG Critical Materials N.V. Publishes 2024 Annual Report

Written by Customer Service on March 12, 2025. Posted in Public Companies.

Amsterdam, 12 March 2025 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has published its 2024 Annual Report. The 2024 Annual Report is available to investors and other interested parties via the AMG website (www.amg-nv.com). Hard copies of the 2024 Annual Report can be requested by contacting AMG via email at info@amg-nv.com. About AMG AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO2 in aerospace engines, as well as critical materials addressing CO2 reduction in a variety of other end use markets. AMG’s...

Societe Generale: Renewals and appointments of board members proposed to the General Meeting to be held on 20 May 2025

Written by Customer Service on March 12, 2025. Posted in Public Companies.

RENEWALS AND APPOINTMENTS OF BOARD MEMBERS PROPOSED TO THE GENERAL MEETING TO BE HELD ON 20 MAY 2025 Press release Paris, 12 March 2025 The Board of Directors of Societe Generale, upon the proposal of the Nomination and Corporate Governance Committee, approved the proposed renewals and appointments of board members ahead of the Shareholders’ General Meeting to be held on 20 May 2025. The Board of Directors invites the General Meeting to be held on 20 May 2025 to vote to replace two female directors (Mrs Lubomira Rochet, resigning since 12 September 2024, and Mrs Alexandra Schaapveld, end of her third term as an independent director) and to renew three male directors (Mr. William Connelly, Mr. Henri Poupart-Lafarge and Mr. Sébastien Wetter). Mrs Ingrid-Helen Arnold will be proposed for her first term as an independent Director. Aged 56...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals